Answers are grounded in this paper and cite their sources.
Background This study conducted longitudinal surveillance of the under-recognized pathogen Kerstersia gyiorum to characterize its epidemiology and antimicrobial resistance patterns, and to provide preliminary data that may inform clinical awareness and future research. Methods This retrospective study analyzed K. gyiorum isolates recovered at a single center between 2019 and 2025. As species-specific antimicrobial susceptibility testing (AST) breakpoints are unavailable for K. gyiorum , proportions of resistant isolates were derived using surrogate breakpoints. Statistical analyses were performed using WHONET 2025, Microsoft Excel 2021, and R 4.5.2. The exact conditional Cochran-Armitage test was used to assess annual variations in resistance. Fisher’s exact test was applied for head‑to‑head comparisons of the proportions of resistant isolates between intensive care unit (ICU) and non‑ICU isolates, with risk differences (RDs) and 95% confidence intervals (CIs) calculated to estimate effect sizes. Results Over the 7‑year study period, 34 K. gyiorum isolates were recovered. Annual counts increased in the early years, peaked in 2022 (9 isolates), and then remained relatively stable (5–6 isolates per year). The majority of patients were elderly (all > 50 years), with 28 (82.35%) aged ≥ 80 years; 23 (67.65%) were male, 29 (85.29%) were admitted to the ICU, and 25 (73.53%) had pulmonary involvement. K. gyiorum isolates were frequently co-isolated with other pathogens, most commonly Pseudomonas aeruginosa (27, 79.41%), Proteus mirabilis (23, 67.65%), and Klebsiella pneumoniae (22, 64.71%). The highest overall proportion of resistant isolates was observed for ciprofloxacin (16/34, 47.06%). Proportions of resistant isolates varied across the study years. For most antimicrobials, ICU isolates numerically exhibited a higher proportion of resistant isolates than non-ICU isolates, with the exception of aztreonam, ciprofloxacin, and levofloxacin. The largest positive and negative RDs were observed for ticarcillin/clavulanic acid (20.00%) and ciprofloxacin (-15.17%), respectively. Conclusions This single-center descriptive study described the patient profiles and antimicrobial resistance patterns of K. gyiorum isolates at our institution during 2019–2025. We suggest that timely sampling, identification, and susceptibility testing be considered for patients with similar epidemiological characteristics, and that continuous surveillance data be promptly reported to raise awareness of rare organisms. As all isolates were polymicrobial, these data reflect isolation and colonization patterns rather than proven clinical infection. Moreover, the resistance analyses are based on surrogate breakpoints and changing AST panels, and the observed year-to-year changes may represent stochastic variation or testing artifacts rather than true epidemiological evolution. Therefore, this study provides preliminary, hypothesis-generating data on K. gyiorum -positive isolates that may inform future research.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: